Lung cancer trial aims to optimize treatment sequence for better life quality
NCT ID NCT06486142
First seen May 14, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This study looks at the best order to give EGFR-inhibitor drugs to people with advanced lung cancer that cannot be cured. About 200 participants will be assigned to different treatment sequences, and researchers will track how long the cancer stays controlled, side effects, and quality of life. Blood and tumor samples will also be analyzed to find markers that could guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne university hospital
RECRUITINGLund, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.